Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis

Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis

Abstract Introduction Ixekizumab, a humanized interleukin-17A antibody, has shown efficacy in ankylosing spondylitis (AS), with a greater proportion of ixekizumab-treated patients achieving an ASAS40 (Assessment of Spondyloarthritis International Society 40) endpoint compared to placebo. An ASAS40 r...

Full description

Bibliographic Details
Main Authors: Philip Mease, Jessica A. Walsh, Xenofon Baraliakos, Robert Inman, Kurt de Vlam, James Cheng-Chung Wei, Theresa Hunter, Gaia Gallo, David Sandoval, Fangyi Zhao, Yan Dong, Rebecca Bolce, Helena Marzo-Ortega
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-06-01
Series:Rheumatology and Therapy
Subjects:
Ankylosing spondylitis
ASAS40
Axial spondyloarthritis
Fatigue
Inflammation
Ixekizumab
Online Access:http://link.springer.com/article/10.1007/s40744-019-0165-3

Internet

http://link.springer.com/article/10.1007/s40744-019-0165-3

Similar Items